Home | FCA & regulatory news | British English edition
Trade Hub UK

Independent coverage of UK markets, FCA policy and institutional trading
AD Bank of England Statistics AD Investing.com Markets AD LSEG Data AD CME Group Education
Venues & MTFs

Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up

City noticeboard, Trade Hub UK (2026-10-19): Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up (RTTNews) - Disc Medicine, Inc. (IRON) is scheduled to release topline… Primary source: original at Nasdaq Market Structure (nasdaq.com).

By Nasdaq Market Structure

Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up

(RTTNews) - Disc Medicine, Inc. (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial evaluating Bitopertin in patients with erythropoietic protoporphyria (EPP), a rare inherited blood disorder. The company will discuss the findings during a corporate

Read at source

Read also
  1. Veradermics To Review Phase 3 Study 304 Results For VDPHL01 In Male Pattern Hair Loss; Stock Up
  2. Is Visa Stock Still a Buy After Gaining 14% This Year?
  3. Taiwan Stock Market May Open Under Water On Monday
  4. If I Could Only Own 1 Artificial Intelligence (AI) Memory Stock for the Next 5 Years, It Wouldn't Be Micron.
  5. Propanc Reports Preclinical Data For PRP In Chemoresistance; Phase 1 Set For Q1 '27

Source: Nasdaq Market Structure